In a cohort of 102 critically ill patients with COVID-19-associated sepsis treated with TPE, we observed consistent IL-6 and D-dimer reductions—particularly among those with high baseline cytokine and thrombotic burden—without parallel, robust improvements in short-term organ-failure scores or mortality. The gene discussed is IL6; the disease is COVID-19.